Monograph Details
|
|
Central Nervous System
> Insomnia
|
|
LUNESTA |
| Manufacturer |
|
Sepracor, Inc. |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Pyrrolopyrazine hypnotic. |
| Generic Name |
|
Eszopiclone 1mg, 2mg, 3mg; tabs. |
| Indications |
|
Insomnia. |
| Children |
<18yrs: not recommended.
|
| Adults |
|
≥18yrs: 2–3mg immediately at bedtime [take only if able to get full night's sleep (8 hours) before becoming active again]. Elderly: initially 1mg for patients with difficulty falling asleep; may give 2mg if patient has difficulty staying asleep. Severe hepatic impairment: initially 1mg; max 2mg/dose. Concomitant CYP3A4 inhibitors (see Interactions): initial max 1mg/dose; may increase to 2mg if needed. Effect delayed if taken with high-fat/heavy meals. |
| Precautions |
|
Depression. Behavioral changes. Drug or alcohol abuse. Compromised respiratory function. Conditions that affect metabolism or hemodynamic response. Write Rx for smallest practical amount. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Potentiates CNS depression with alcohol, other CNS depressants. Potentiated by CYP3A4 inhibitors (eg, itraconazole). May be antagonized by CYP3A4 inducers (eg, rifampicin). |
| Adverse Reactions |
|
Unpleasant taste, CNS effects, complex sleep-related behaviors (eg, sleep-driving), GI upset, dry mouth, infection; anaphylaxis, angioedema, others (see literature). |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
